ticker stringlengths 2 5 | disease stringlengths 3 196 | stage stringclasses 15 values | date stringlengths 6 8 | catalyst stringlengths 20 963 | label int64 4 6 |
|---|---|---|---|---|---|
RVMD | Solid Tumors | Phase 1 | 10/13/23 | Phase 1 preliminary data shared at AACR-NCI-EORTC reported a median time to response of 1.3 months, and median time on treatment of 3.5 months in NSCLC, with a median time to response of 1.4 months, and median time on treatment of 2.4 months in CRC, noted October 13, 2023. | 6 |
IMUX | Relapsing-remitting multiple sclerosis (RMS) | Phase 2 | 10/13/23 | Phase 2 data presented at ECTRIMS reported that VidoCa was associated with a Nfl reduction from baseline up to W6 of -3% for the pooled 30 and 45mg VidoCa group compared to +2.5% for placebo, and up to W24 of -19% and +7%, respectively, noted October 13, 2023. | 6 |
AVIR | Dengue | Phase 2 | 4/17/23 | Additional Phase 2 data presented at ECCMID reported that AT-752 was well tolerated and had no clinically relevant effects on cardiac repolarization, heart rate, PR or QRS intervals, noted April 17, 2023. | 6 |
INZY | ENPP1 deficiency | Phase 2 | 9/26/23 | Phase 2 interim data from cohort 1-3 reported an improvement in the Global Impression of Change (GIC) observed in all three dose cohorts in ABCC6 Deficiency (PXE) trial, noted September 26, 2023. | 6 |
MRK | Cervical Cancer | Approved | 10/13/21 | Approved October 13, 2021. | 6 |
NVS | HR+/HER2− metastatic breast cancer | Phase 2 | 12/6/22 | Phase 2 data reported that treatment doubled the median PFS vs. combination CT at 24.0 months compared to 12.3 months, noted December 6, 2022. | 6 |
RHHBY | Hepatocellular Carcinoma (HCC), Solid tumors | Phase 1 | 4/17/23 | Additional biomarker data presented at AACR reported on-target changes in gene signatures in the peripheral blood that were dependent upon drug exposure levels, noted April 17, 2023. | 6 |
REGN | Wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR) | Approved | 8/18/23 | Approved August 18, 2023. | 6 |
IONS | Cardiovascular (CV) risk reduction and hypertriglyceridemia | Phase 2b | 11/24/21 | Phase 2b updated data demonstrated that in the dose-ranging study in subjects with elevated non-HDL-C and triglycerides (TG), the study met its primary endpoint, achieving a statistically significant reduction in non-HDL-C at all doses tested at 24 weeks, compared to placebo, noted November 24, 2021. | 6 |
SVRA | Nontuberculous mycobacteria (NTM) | Phase 2 | 3/12/20 | Phase 2 top-line data released March 12, 2020. | 5 |
ALNY | IgA nephropathy | Phase 2 | 8/29/22 | Phase 2 new results demonstrated an equivalent 36% reduction in 24-hour urine total protein and a higher proportion, 32 vs 13%, of patients treated in comparison to placebo, respectively, achieving greater than or equal to 50% reduction in 24-hour UPCR, noted August 29, 2022. | 6 |
SUPN | Bipolar depression | Phase 3 | 5/5/20 | Phase 3 development has been terminated - May 5, 2020. | 4 |
DVAX | Asthma | Phase 2a | 11/29/18 | Phase 2a trial did not meet primary endpoint - November 29, 2018. | 4 |
ABBV | Non-radiographic axial spondyloarthritis | Approved | 10/21/22 | FDA. Approved on October 21, 2022. | 6 |
ACOR | Parkinson’s disease (PD) | Phase 3 | 11/15/17 | Phase 3 data due 1Q 2018. Noted November 15, 2017 seven cases of sepsis, five of which were fatal. | 5 |
RHHBY | Third-line advanced or metastatic colorectal cancer | Phase 3 | 5/10/18 | Phase 3 data released May 10, 2018. Primary endpoint not met. | 4 |
GSK | Meningitis, meningococcal disease caused by serogroups A, B, C, W and Y | Phase 3 | 5/12/23 | Phase 3 data reported that the trial met all primary endpoints, noted May 12, 2023. | 5 |
HALO | Generalized Myasthenia Gravis (gMG) | Approved | 6/20/23 | FDA Approved on June 20, 2023. | 6 |
AZN | Factor Xa inhibitor reversal agent | Approved | 12/31/18 | Prior Approval Supplement (PAS) FDA Approval announced December 31, 2018. | 6 |
VRTX | Beta-thalassemia | Phase 1/2 | 6/11/21 | Phase 1/2 data presented at EHA meeting June 11, 2021. All 15 patients were transfusion independent with follow-up ranging from 4 to 26 months after CTX001 infusion and had clinically meaningful improvements in total hemoglobin from 8.9 to 16.9 g/dL and fetal hemoglobin from 67.3% to 99.6% at last visit. | 6 |
EGRX | Exertional heat stroke (EHS) | CRL | 8/10/20 | CRL announced August 10, 2020. | 5 |
BCRX | Hereditary Angioedema | Phase 2 | 5/7/23 | Additional long-term 96 weeks at 150mg data reported that the attack-free status was consistently high with ORLADEYO 150 mg regardless of patients' age, gender and prior prophylactic treatment, noted May 7, 2023. | 6 |
RARE | Osteogenesis Imperfecta | Phase 2 | 10/14/23 | Additional Phase 2 data reported that the annualized fracture rate across all 24 patients in the Phase 2 portion of the study was reduced by 67%, noted October 14, 2023. | 6 |
KOD | Treatment-Naive Wet Age-Related Macular Degeneration (AMD) | Phase 3 | 10/13/23 | Phase 3 data presented at the Retina Society meeting reported a favorable safety profile with low rates of intraocular inflammation and no cases of intraocular inflammation with vasculitis or vascular occlusion, noted October 13, 2023. | 6 |
VRTX | Children with cystic fibrosis (CF) ages 1 month to less than four months old | Approved | 5/3/23 | FDA approved on May 3, 2023. | 6 |
FDMT | Wet age-related macular degeneration (AMD) | Phase 1/2 | 7/29/23 | Phase 1/2 additional dose response data demonstrated in favor of highest tested dose of 3E10 vg/eye, including 100% reduction in supplemental anti-VEGF injections (4 of 4 evaluable patients injection-free) and a clinically meaningful reduction in central subfield thickness (CST) at 36 weeks in patient population with high anti-VEGF need, noted July 29, 2023. | 6 |
HRMY | Excessive daytime sleepiness associated with Prader-Willi Syndrome (PWS) | Phase 2 | 7/20/23 | EoP2 meeting completed, noted July 20, 2023 | 6 |
MBIO | B-cell Non-Hodgkin Lymphoma & Chronic Lymphocytic Leukemia (CLL) | Phase 1/2 | 8/16/23 | Initial Phase 1/2 data reported clinical responses from four of four indolent lymphoma patients, including complete response in follicular lymphoma patient previously treated with CD19 CAR-T cell therapy, noted August 16, 2023. | 6 |
CADL | Pancreatic Cancer | Phase 2 | 11/3/23 | Phase 2 initial overall survival and immunological biomarker data presented at SITC revealed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma (PDAC) after experimental treatment with CAN-2409, noted November 3, 2023. | 6 |
JNJ | metastatic hormone-naïve prostate cancer (mHNPC) | Approved | 2/8/18 | sNDA approval announced February 8, 2018. | 6 |
AZN | COVID-19 | Phase 3 | 1/26/23 | FDA no longer allows treatment to be used as Emergency Use Authorization (EUA) due to the lack of effectiveness against the currently circulating variants, noted January 26, 2023. | 6 |
ABBV | Waldenström’s Macroglobulinemia | Approved | 1/29/15 | Approved January 29, 2015 - PCYC | 6 |
EQRX | CNS metastases and EGFR-mutated non-small cell lung cancer (NSCLC) | Phase 3 | 6/6/22 | Phase 3 data reported that CNS PFS events were observed in 11 patients (38%) treated, and the confirmed CNS ORR were 82.8% and 75.0% in patients treated with Au and G, respectively, noted June 6, 2022. | 6 |
AGEN | Solid cancers | Phase 1 | 6/4/18 | Phase 1 presentation at ASCO 2018. 31% ORR. | 5 |
AGEN | Advanced Solid tumors, Colorectal cancer | Phase 1b | 10/21/23 | Phase 1b data presented at ESMO reported an overall response rate (ORR) of 24% was observed, compared to 2.8% reported with standard of care (SOC), and a 12-month overall survival (OS) of 74% and median OS (mOS) not yet reached, noted October 21, 2023. | 6 |
NGM | Non-alcoholic steatohepatitis (NASH) | Phase 2b | 5/24/21 | Phase 2b top-line data released May 24, 2021. Primary endpoint not met. | 4 |
ALXO | Head and neck squamous cell carcinoma (HNSCC) | Phase 2 | 11/9/21 | Phase 2 clinical data showed that patients with 1L HNSCC who have not received prior treatment for their advanced disease (n=13), the dose demonstrates an initial ORR of 38.5% with a 12-month OS rate of 87.5% and mOS not reached in combination with pembrolizumab + 5FU + platinum. These results compare favorably with benchmark survival data from standard pembrolizumab + chemotherapy, noted November 9, 2021. | 6 |
SNDX | Triple negative breast cancer (TNBC) | Phase 2 | 3/7/19 | Phase 2 top-line data March 7, 2019 failed to meet endpoints. | 4 |
AZN | Non-small cell lung cancer (NSCLC) | Approved | 11/11/22 | Approved November 11, 2022. | 6 |
RHHBY | Relapsed/Refractory Multiple Myeloma (RRMM) | Phase 1 | 12/12/22 | Phase 1 1 year data reported that the best overall response (BOR) achieved was: stringent complete response (sCR) in 7 patients, CR in 3 patients, very good partial response (VGPR) in 5 patients, and PR in 1 patient, noted December 12, 2022. | 6 |
SNY | Hidradenitis suppurativa / atopic dermatitis | Phase 1 | 12/14/22 | Phase 1 data reported that a 37% mean reduction in EASI in AD and 42% of HS patients has AN Count 0/1/2, noted December 14, 2022. | 6 |
VBIV | Hepatitis B vaccine | Phase 3 | 9/21/22 | Additional Phase 3 data reported that treatment may be effective only in low level HBsAg carriers with a low tolerizing effect of HBsAg, noted September 21, 2022. | 6 |
RCUS | Non-small cell lung cancer (NSCLC) | Phase 2 | 6/5/23 | Phase 2 presentation at ASCO reported one complete response in the monotherapy and in the DZ combo, noted June 5, 2023. | 6 |
TAK | Negative symptoms of schizophrenia | Phase 2 | 3/2/21 | Phase 2 trial did not meet primary endpoint - March 2, 2021. | 4 |
GILD | Large B-cell lymphoma (LBCL) after one prior line of therapy who were deemed ineligible for high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) | Phase 2 | 9/18/23 | Phase 2 trial met its primary endpoint, noted September 18, 2023. | 5 |
CLLS | Large B-cell lymphoma | Phase 1 | 6/15/23 | Additional data reported at ICML across all 33 patients the CR rate was 42% with 30% maintaining a CR at Month 6. Results indicated complete responses are more common with lymphodepletion regimens containing 90 mg of ALLO-647 (FCA90). Median duration of response for both the overall population and the patients treated with the Phase 2 regimen (n=12) was 23.1 months, noted June 15, 2023. | 6 |
XERS | Type 1 diabetes | Phase 2 | 6/18/20 | Phase 2 data released June 18, 2020. 62% reduction of hyperglycemia after a glucose challenge. | 6 |
ARGX | Myasthenia gravis (MG) | Approved | 12/17/21 | Approved December 17, 2021. | 6 |
ALDX | Dry eye disease | Phase 3 | 7/12/22 | Phase 3 crossover results reported that met both primary endpoints, noted July 12, 2022. | 5 |
TEVA | Osteoarthritis pain of the hip or knee | Phase 3 | 8/5/20 | Phase 3 data achieved the co-primary endpoints for fasinumab 1 mg monthly. Fasinumab every two months did not reach statistical significance - August 5, 2020. | 5 |
SRPT | Duchenne Muscular Dystrophy | Approved | 6/22/23 | FDA acelerated Approval on June 22, 2023. | 6 |
JNCE | Non-small cell lung cancer and bladder cancer | Phase 2 | 11/2/20 | Phase 2 interim analysis noted the trial will not meet pre-specified interim criteria for continuation of enrollment - November 2, 2020. | 4 |
PFE | Spinal Muscular Atrophy (SMA) | Phase 3 | 9/14/23 | Phase 3 trial to continue dosing, noted November 9, 2022. Phase 3 dosing completed, noted September 14, 2023. | 5 |
ABBV | Preventive treatment of migraine | Approved | 4/18/23 | Approved April 17, 2023. | 6 |
MRK | HER2-positive gastric or Gastroesophageal junction (GEJ) adenocarcinoma | Phase 3 | 10/20/23 | Phase 3 trial data presented at ESMO demonstrated a statistically significant PFS improvement in advanced HER2-positive gastric or GEJ adenocarcinoma in tumors expressing PD-L1 (Combined Positive Score [CPS] ≥1) compared to trastuzumab and chemotherapy alone October 20, 2023. | 6 |
RHHBY | Coronavirus COVID-19 | Phase 3 | 7/29/20 | Phase 3 trial did meet primary endpoint - July 29, 2020. | 6 |
PRQR | Autosomal dominant retinitis pigmentosa (adRP) | Phase 1/2 | 11/18/21 | Phase 1/2 data reported 3 cases of cataract worsening, with maximum benefit in BCVA observed after 5 weeks and declined thereafter. A mean BCVA benefit of +1.4 letters was reported across all subjects. In doses 75 - 300µg, the mean BCVA benefit was +5 letters, maximum benefit observed was +7 letters, noted November 18, 2021. | 6 |
NVS | Acute myeloid leukemia (AML) | Approved | 4/28/17 | Priority review granted November 14, 2016. Approval announced April 28, 2017. | 6 |
AVTX | Non-Eosinophilic Asthma (NEA) | Phase 2 | 6/26/23 | Phase 2 did not meet the primary endpoint measured by reduction in asthma related events compared to placebo, noted June 26, 2023. | 6 |
TPST | Hepatocellular carcinoma (HCC) | Phase 1/2 | 10/11/23 | Phase 1b/2 trial had a confirmed objective response rate of 30% for the TPST-1120 triplet arm versus 13.3% for the atezolizumab + bevacizumab control arm; duration of response ("DoR") has not yet been reached, noted October 11, 2023. | 6 |
HCM | Intrahepatic cholangiocarcinoma (IHCC) | Phase 2 | 5/25/23 | Phase 2 first in human data reported that the best overall response by investigator assessment was confirmed partial response in seven (31.8%) pts and stable disease in an additional 12 pts, noted May 25, 2023. | 5 |
CYCN | Alzheimer's disease with vascular features (ADv) | Phase 2a | 5/11/23 | Phase 2a data was inconclusive, noted May 11, 2023. | 5 |
MRK | Gastric cancer | Phase 3 | 4/25/19 | Phase 3 data released April 25, 2019 noted that monotherapy arm met noninferiority primary endpoint. Combo arm did not meet OS/PFS endpoints. | 5 |
BIIB | Small Fiber Neuropathy | Phase 2 | 9/16/21 | Phase 2 200mg dosing data met primary endpoint, did not meet statistical significance for secondary endpoints. Phase 2 330 mg dosing data did not meet the primary endpoint or secondary endpoints, September 16, 2021. | 4 |
HRMY | Developmental and Epileptic Encephalopathies (DEE) | Phase 2 | 9/18/19 | Phase 2 top-line data released September 18, 2019. 10/46 reported a serious adverse event (SAE). | 4 |
GTHX | Second/third-line small-cell lung cancer | Approved | 2/12/21 | FDA approval announced February 12, 2021. | 6 |
VRCA | Basal cell carcinoma | Phase 2 | 8/10/23 | Phase 2 data presented at AAD Innovation Academy show consistency inclinical and histological clearance of treated BCC lesions was observed by Day 49 post-treatment with the 8 mg dose of VP-315, with 4 of 6 subjects (67%) showing complete tumor clearance, noted August 10, 2023. | 6 |
AZN | Heart failure | Approved | 5/5/20 | FDA Approval announced May 5, 2020. | 6 |
ICPT | NASH patients with compensated cirrhosis | Phase 3 | 8/2/23 | NASH Programs discontinued, noted August 2, 2023. | 4 |
SGEN | Frontline CD30-positive mature T-cell lymphomas - cancer | Approved | 11/16/18 | FDA Approval announced November 16, 2018. | 6 |
LGND | Postpartum Depression - moderate | Approved | 3/19/19 | FDA approval announced March 19, 2018. | 6 |
AADI | Open-angle glaucoma (OAG) | Phase 2 | 12/11/20 | Phase 2 data met primary endpoint with twice-daily dose group but not with once-daily group. | 6 |
OVID | Adolescents with Angelman syndrome | Phase 3 | 12/1/20 | Phase 3 trial did not meet primary endpoint - December 1, 2020. | 4 |
LPCN | Postpartum Depression | Phase 1 | 5/16/23 | Pilot clinical PK bridge study data reported that treatment is well-tolerated with no hypoxia or sedation-related adverse events, noted May 16, 2023. | 6 |
AZN | Paroxysmal nocturnal hemoglobinuria (PNH) | Approved | 12/21/18 | FDA approval announced December 21, 2018. | 6 |
ZVRA | Vascular Ehlers-Danlos Syndrome | CRL | 6/25/19 | CRL issued June 25, 2019. | 5 |
HCM | Primary immune thrombocytopenia (ITP) | Phase 3 | 8/21/23 | Phase 3 trial met is primary endpoint, noted August 21, 2023. | 5 |
PHGE | Acne | Phase 2 | 11/15/21 | Program to be discontinued to focus resources on CF and AD programs, noted November 15, 2021. | 4 |
PTCT | Spinal Muscular Atrophy (SMA) Type 1 | Approved | 8/7/20 | FDA Approval announced August 7, 2020. | 6 |
MRK | COVID-19 | Phase 3 | 4/1/22 | Phase 3 final analysis reported that at day 3 infectious SARS-CoV-2 was detected in 0.0% of treated patients, compared with 21.8% with placebo, noted April 1, 2022. | 6 |
OTIC | Hearing loss | Phase 1/2 | 12/17/20 | Phase 1/2 data released December 17, 2020. 6 out of 9 (67%) patients demonstrated a clinically-meaningful improvement on at least one of the three SIN tests at both Days 57 and 85 versus 0 out of 8 (0%) for placebo. | 6 |
OLMA | Breast Cancer | Phase 2 | 5/11/23 | Phase 2 data presented at ESMO Breast Cancer reported that partial responses were observed in five patients, with 59% patients remaining on treatment, noted May 11, 2023. | 6 |
NVCT | Ovarian Clear Cell Carcinoma | Phase 1 | 10/13/23 | Phase 1 data presented at AACR-NCI-EORTC reported that NXP800 induced phosphorylation of eIF2a via activation of the stress activated kinase GCN2, noted October 13, 2023. | 6 |
ABBV | Marginal zone lymphoma | Approved | 1/19/17 | sNDA filing under priority review approved January 19, 2017. | 6 |
GSK | Ovarian cancer | Approved | 10/23/19 | FDA Approval announced October 23, 2019. | 6 |
OKYO | Dry Eye Disease | Phase 2 | 10/5/23 | Phase 2 data reported a dropout rate at 5.4% and that treatment was well tolerated, noted October 5, 2023. | 6 |
LIAN | Hypertrophic cardiomyopathy (HCM) | Approved | 4/28/22 | Approved April 28, 2022. | 6 |
APTX | Post-traumatic stress disorder (PTSD) | Phase 2 | 10/19/20 | Phase 2 data released October 19, 2020. Primary endpoint met. | 6 |
PFE | Pneumococcal + Covid-19 vaccine dual administration in 65< | Phase 3 | 1/12/22 | Phase 3 top-line results noted that responses for all 20 serotypes and to the covid-19 vaccine were similar, with a safety profile similar to the booster dose, noted January 12, 2022. | 5 |
PFE | Generalized anxiety disorder (GAD) | Phase 3 | 2/10/20 | Phase 3 trial did not meet primary endpoint. | 4 |
NOVN | Acne vulgaris | Phase 3 | 1/27/17 | Phase 3 top-line data released January 27, 2017. Met one of three co-primary endpoints in NI-AC301 trial. Met all endpoints in NI-AC302 trial. | 6 |
AMGN | Behçet’s Disease | Approved | 7/19/19 | FDA Approval announced July 19, 2019. | 6 |
BIIB | Rheumatoid arthritis (RA) | Approved | 9/29/23 | FDA Biosimilar of ACTEMRA approved on September 29, 2023. | 6 |
SPRY | Allergic reactions (type I) including anaphylaxis | CRL | 9/20/23 | CRL announced September 20, 2023. | 5 |
CVM | Head and Neck cancer | Phase 3 | 10/30/23 | Phase 3 data finalized target population data resulted in risk of death cut in half at five years versus the control, 28.6% absolute 5-year overall survival benefit versus control, 0.349 hazard ratio vs control , noted October 30, 2023. | 5 |
ALDX | Noninfectious anterior uveitis | Phase 3 | 6/25/19 | Phase 3 data did not meet endpoints - June 25, 2019. | 4 |
MRK | Cervical cancer | Approved | 6/12/18 | Approval announced June 12, 2018. | 6 |
NVO | Type 2 diabetes | Approved | 12/5/17 | Approval announced December 5, 2017. | 6 |
CYTK | Amyotrophic lateral sclerosis (ALS) | Phase 3 | 3/31/23 | DMC review recommended the discontinuation of the trial due to futility, noted March 31, 2023. | 4 |
ERAS | Colorectal cancer and gastrointestinal (GI) cancer | Phase 1/2 | 6/5/23 | Initial Phase 1b/2 data showed a 50% response rate, including two confirmed partial responses (cPR) and one unconfirmed partial response (uPR), and 67% disease control rate in EC-naïve response evaluable patients at the highest dose of ERAS-007 tested (100 mg BID-QW), development deprioritized as clinical efficacy data do not support continued evaluation, noted June 5, 2023 | 6 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.